- Glatiramer acetate
-
- $10.00 / 1g
-
2024-04-24
- CAS:147245-92-9
- Min. Order: 10g
- Purity: 99%
- Supply Ability: 300tons
- Glatiramer acetate
-
- $35.00/ kg
-
2024-03-16
- CAS:147245-92-9
- Min. Order: 1kg
- Purity: 99.8%
- Supply Ability: 200tons/year
- Glatiramer acetate
-
- $2.00 / 1KG
-
2023-08-16
- CAS:147245-92-9
- Min. Order: 1KG
- Purity: >99%
- Supply Ability: 2000T
|
| | Glatiramer acetate Basic information |
| | Glatiramer acetate Chemical Properties |
| Melting point | >239°C (dec.) | | storage temp. | Refrigerator | | solubility | Methanol (Slightly), Water (Slightly) | | form | Solid | | color | White to Off-White | | CAS DataBase Reference | 147245-92-9(CAS DataBase Reference) |
| | Glatiramer acetate Usage And Synthesis |
| Originator | Copaxone,Teva Pharmaceuticals,Israel | | Uses | Glatiramer Acetate-Dx is labelled Glatiramer Acetate (G406800) which is a random basic synthetic copolymer of L-alanine, L-lysine, l-glutamic acid and L-tyrosine. Glatiramer acetate is an immunomodulator used in treatment of multiple sclerosis. | | Uses | Glatiramer acetate is a random basic synthetic copolymer of L-alanine, L-lysine, l-glutamic acid and L-tyrosine in a molar ratio of 6:1.9:4.7:1. Glatiramer acetate is an immunomodulator used in treatment of multiple sclerosis. | | Manufacturing Process | Glatiramer Acetate is water soluble copolypeptide with molecular weight
15,000-25,000.
Copolymer is prepared by copolymerization of the N-carboxyanhydrides of
tyrosine, alanine, lysine, and glutamic acid. The polymerisation was carried
out at ambient temperature in anhydrous dioxane with diethylamine as
initiator. Glatiramer Acetate have the ratio alanin:glutamic acid:lysine:tyrosine
= 1:6:4.54:2. | | Brand name | Copaxone (Teva). | | Therapeutic Function | Immunomodulator | | Clinical Use | Immunomodulating drug:
Treatment for patients at a high risk of developing
multiple sclerosis and for reduction in relapses in
ambulatory patients | | Metabolism | A substantial fraction of a subcutaneous dose of
glatiramer is believed to be hydrolysed locally. Some of
the injected dose is also presumed to enter the lymphatic
system, either intact or partially hydrolysed. |
| | Glatiramer acetate Preparation Products And Raw materials |
|